Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for hospitalized COVID-19 respiratory infection or non-COVID-19 ARDS
ACTRN12621000637842Phase 3Terminated
- Sponsor
- University of Sydney
- Start
- Dec 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing Colchicine + standard of care with Standard of care (2 arms). Started Dec 2021; status: terminated.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ACTRN12621000637842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000637842.